PortalPublikationenRegional differences in patient characteristics and outcomes...

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study

Standard

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study. / Hohnloser, Stefan H; Calkins, Hugh; Willems, Stephan; Verma, Atul; Schilling, Richard; Okumura, Ken; Nordaby, Matias; Kleine, Eva; Biss, Branislav; Gerstenfeld, Edward P; RE-CIRCUIT Investigators.

in: J INTERV CARD ELECTR, Jahrgang 55, Nr. 2, 08.2019, S. 145-152.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hohnloser, SH, Calkins, H, Willems, S, Verma, A, Schilling, R, Okumura, K, Nordaby, M, Kleine, E, Biss, B, Gerstenfeld, EP & RE-CIRCUIT Investigators 2019, 'Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study', J INTERV CARD ELECTR, Jg. 55, Nr. 2, S. 145-152. https://doi.org/10.1007/s10840-019-00518-x

APA

Hohnloser, S. H., Calkins, H., Willems, S., Verma, A., Schilling, R., Okumura, K., Nordaby, M., Kleine, E., Biss, B., Gerstenfeld, E. P., & RE-CIRCUIT Investigators (2019). Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study. J INTERV CARD ELECTR, 55(2), 145-152. https://doi.org/10.1007/s10840-019-00518-x

Vancouver

Hohnloser SH, Calkins H, Willems S, Verma A, Schilling R, Okumura K et al. Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study. J INTERV CARD ELECTR. 2019 Aug;55(2):145-152. https://doi.org/10.1007/s10840-019-00518-x

Bibtex

@article{9b3bee3e413b4e748cc3efd76df18b07,
title = "Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study",
abstract = "PURPOSE: To describe regional differences in patient characteristics, ablation procedures, and bleeding events in the RE-CIRCUIT study. RE-CIRCUIT was a prospective, multicenter study that captured data from different regions, providing an opportunity to understand the practices followed in various regions. The incidence of major bleeding events (MBEs) was significantly lower with uninterrupted dabigatran versus uninterrupted warfarin.METHODS: Patients were randomized to receive dabigatran 150 mg twice daily or warfarin. Ablation was performed with uninterrupted anticoagulation for 8 weeks after the procedure. Regions were Western Europe, Eastern Europe, North America, and Asia.RESULTS: Of 704 patients screened across 104 sites, 635 underwent catheter ablation (dabigatran, 317; warfarin, 318). Patient characteristics were different across various regions. Patients from North America had the highest prevalence of atrial flutter (33%), coronary artery disease (29%), diabetes mellitus (18%), and previous myocardial infarction (9%). Hypertension was most prevalent in Eastern Europe (75%), as was congestive heart failure (40% vs 2% in Western Europe). Pulmonary vein isolation alone was the preferred technique used in most patients (86% in North America and 75-83% elsewhere) and radio frequency was the preferred energy source. The major outcome measure, incidence of MBEs during and up to 2 months after the procedure, was consistently lower with uninterrupted dabigatran versus warfarin, irrespective of regions and their procedural differences, and different ablation techniques utilized.CONCLUSIONS: This analysis shows that the benefits of dabigatran over a vitamin K antagonist in patients undergoing atrial fibrillation ablation are consistent across all geographic regions studied.TRIAL REGISTRATION: NCT02348723 (https://clinicaltrials.gov/ct2/show/NCT02348723).",
keywords = "Aged, Anticoagulants/administration & dosage, Asia, Atrial Fibrillation/surgery, Catheter Ablation/methods, Comorbidity, Dabigatran/administration & dosage, Europe, Female, Humans, Male, Middle Aged, North America, Prospective Studies, Warfarin/administration & dosage",
author = "Hohnloser, {Stefan H} and Hugh Calkins and Stephan Willems and Atul Verma and Richard Schilling and Ken Okumura and Matias Nordaby and Eva Kleine and Branislav Biss and Gerstenfeld, {Edward P} and {RE-CIRCUIT Investigators}",
year = "2019",
month = aug,
doi = "10.1007/s10840-019-00518-x",
language = "English",
volume = "55",
pages = "145--152",
journal = "J INTERV CARD ELECTR",
issn = "1383-875X",
publisher = "Springer Netherlands",
number = "2",

}

RIS

TY - JOUR

T1 - Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study

AU - Hohnloser, Stefan H

AU - Calkins, Hugh

AU - Willems, Stephan

AU - Verma, Atul

AU - Schilling, Richard

AU - Okumura, Ken

AU - Nordaby, Matias

AU - Kleine, Eva

AU - Biss, Branislav

AU - Gerstenfeld, Edward P

AU - RE-CIRCUIT Investigators

PY - 2019/8

Y1 - 2019/8

N2 - PURPOSE: To describe regional differences in patient characteristics, ablation procedures, and bleeding events in the RE-CIRCUIT study. RE-CIRCUIT was a prospective, multicenter study that captured data from different regions, providing an opportunity to understand the practices followed in various regions. The incidence of major bleeding events (MBEs) was significantly lower with uninterrupted dabigatran versus uninterrupted warfarin.METHODS: Patients were randomized to receive dabigatran 150 mg twice daily or warfarin. Ablation was performed with uninterrupted anticoagulation for 8 weeks after the procedure. Regions were Western Europe, Eastern Europe, North America, and Asia.RESULTS: Of 704 patients screened across 104 sites, 635 underwent catheter ablation (dabigatran, 317; warfarin, 318). Patient characteristics were different across various regions. Patients from North America had the highest prevalence of atrial flutter (33%), coronary artery disease (29%), diabetes mellitus (18%), and previous myocardial infarction (9%). Hypertension was most prevalent in Eastern Europe (75%), as was congestive heart failure (40% vs 2% in Western Europe). Pulmonary vein isolation alone was the preferred technique used in most patients (86% in North America and 75-83% elsewhere) and radio frequency was the preferred energy source. The major outcome measure, incidence of MBEs during and up to 2 months after the procedure, was consistently lower with uninterrupted dabigatran versus warfarin, irrespective of regions and their procedural differences, and different ablation techniques utilized.CONCLUSIONS: This analysis shows that the benefits of dabigatran over a vitamin K antagonist in patients undergoing atrial fibrillation ablation are consistent across all geographic regions studied.TRIAL REGISTRATION: NCT02348723 (https://clinicaltrials.gov/ct2/show/NCT02348723).

AB - PURPOSE: To describe regional differences in patient characteristics, ablation procedures, and bleeding events in the RE-CIRCUIT study. RE-CIRCUIT was a prospective, multicenter study that captured data from different regions, providing an opportunity to understand the practices followed in various regions. The incidence of major bleeding events (MBEs) was significantly lower with uninterrupted dabigatran versus uninterrupted warfarin.METHODS: Patients were randomized to receive dabigatran 150 mg twice daily or warfarin. Ablation was performed with uninterrupted anticoagulation for 8 weeks after the procedure. Regions were Western Europe, Eastern Europe, North America, and Asia.RESULTS: Of 704 patients screened across 104 sites, 635 underwent catheter ablation (dabigatran, 317; warfarin, 318). Patient characteristics were different across various regions. Patients from North America had the highest prevalence of atrial flutter (33%), coronary artery disease (29%), diabetes mellitus (18%), and previous myocardial infarction (9%). Hypertension was most prevalent in Eastern Europe (75%), as was congestive heart failure (40% vs 2% in Western Europe). Pulmonary vein isolation alone was the preferred technique used in most patients (86% in North America and 75-83% elsewhere) and radio frequency was the preferred energy source. The major outcome measure, incidence of MBEs during and up to 2 months after the procedure, was consistently lower with uninterrupted dabigatran versus warfarin, irrespective of regions and their procedural differences, and different ablation techniques utilized.CONCLUSIONS: This analysis shows that the benefits of dabigatran over a vitamin K antagonist in patients undergoing atrial fibrillation ablation are consistent across all geographic regions studied.TRIAL REGISTRATION: NCT02348723 (https://clinicaltrials.gov/ct2/show/NCT02348723).

KW - Aged

KW - Anticoagulants/administration & dosage

KW - Asia

KW - Atrial Fibrillation/surgery

KW - Catheter Ablation/methods

KW - Comorbidity

KW - Dabigatran/administration & dosage

KW - Europe

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - North America

KW - Prospective Studies

KW - Warfarin/administration & dosage

U2 - 10.1007/s10840-019-00518-x

DO - 10.1007/s10840-019-00518-x

M3 - SCORING: Journal article

C2 - 30758702

VL - 55

SP - 145

EP - 152

JO - J INTERV CARD ELECTR

JF - J INTERV CARD ELECTR

SN - 1383-875X

IS - 2

ER -